GlassScriptPhysician profile
James M Poole
NPI 1124087978
$6,803.80
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,883 · 2020: $511 · 2021: $387 · 2022: $22.47.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $5,172.39 | 2019-2021 | |
| Neos Therapeutics, LP | $940.50 | 2019-2021 | |
| Tris Pharma INC | $402.47 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $125.00 | 2021 | |
| Adlon Therapeutics L.P. | $86.74 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $22.47 | 2022 | |
| Boston Scientific Corporation | $21.76 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.18 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.29 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Poole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.